Search for biomarkers of Alzheimer's disease: Recent insights, current challenges and future prospects

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F19%3A10400049" target="_blank" >RIV/00064165:_____/19:10400049 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/19:10400049 RIV/60461373:22340/19:43918845

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=wroXlE8BNw" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=wroXlE8BNw</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.clinbiochem.2019.04.002" target="_blank" >10.1016/j.clinbiochem.2019.04.002</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Search for biomarkers of Alzheimer's disease: Recent insights, current challenges and future prospects

Popis výsledku v původním jazyce

Due to the trend of prolonged lifespan leading to higher incidence of age-related diseases, the demand for reliable biomarkers of dementia rises. In this review, we present novel biomarkers of high potential, especially those found in blood, urine or saliva, which could lead to a more comfortable patient experience and better time- and cost-effectivity, compared to the currently used diagnostic methods. We focus on biomarkers that might allow for the detection of Alzheimer&apos;s disease before its clinical manifestations. Such biomarkers might be helpful for better understanding the etiology of the disease and identifying its risk factors. Moreover, it could be a base for developing new treatment or at least help to prolong the presymptomatic stage in patients suffering from Alzheimer&apos;s disease. As potential candidates, we present, for instance, neurofilament light in both cerebrospinal fluid and blood plasma or amyloid beta in plasma. Above all, we provide an overview of different approaches to the diagnostics, analyzing patient&apos;s biofluids as a whole using molecular spectroscopy. Infrared and Raman spectroscopy and especially chiroptical methods provide information not only on the chemical composition, but also on molecular structure. Therefore, these techniques are promising for the diagnostics of Alzheimer&apos;s disease, as the accumulation of amyloid beta in abnormal conformation is one of the hallmarks of this disease.

Název v anglickém jazyce

Search for biomarkers of Alzheimer's disease: Recent insights, current challenges and future prospects

Popis výsledku anglicky

Due to the trend of prolonged lifespan leading to higher incidence of age-related diseases, the demand for reliable biomarkers of dementia rises. In this review, we present novel biomarkers of high potential, especially those found in blood, urine or saliva, which could lead to a more comfortable patient experience and better time- and cost-effectivity, compared to the currently used diagnostic methods. We focus on biomarkers that might allow for the detection of Alzheimer&apos;s disease before its clinical manifestations. Such biomarkers might be helpful for better understanding the etiology of the disease and identifying its risk factors. Moreover, it could be a base for developing new treatment or at least help to prolong the presymptomatic stage in patients suffering from Alzheimer&apos;s disease. As potential candidates, we present, for instance, neurofilament light in both cerebrospinal fluid and blood plasma or amyloid beta in plasma. Above all, we provide an overview of different approaches to the diagnostics, analyzing patient&apos;s biofluids as a whole using molecular spectroscopy. Infrared and Raman spectroscopy and especially chiroptical methods provide information not only on the chemical composition, but also on molecular structure. Therefore, these techniques are promising for the diagnostics of Alzheimer&apos;s disease, as the accumulation of amyloid beta in abnormal conformation is one of the hallmarks of this disease.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

<a href="/cs/project/GA17-05292S" target="_blank" >GA17-05292S: Nové krevní biomarkery pro včasnou diagnostiku, prognózu a průběh Alzheimerovy nemoci</a><br>

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Biochemistry

ISSN

0009-9120

e-ISSN

—

Svazek periodika

72

Číslo periodika v rámci svazku

October

Stát vydavatele periodika

CA - Kanada

Počet stran výsledku

13

Strana od-do

39-51

Kód UT WoS článku

000486413800007

EID výsledku v databázi Scopus

2-s2.0-85064078438